Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Adjuvance Technologies Inc
Profile last edited on: 8/18/2020      CAGE: 5NFJ7      UEI: C6L6GD4QGWG9

Business Identifier: Vaccine adjuvant design and manufacturing
Year Founded
2009
First Award
2014
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

116 West 22nd Street Suite 1
New York, NY 10010
Location: Single
Congr. District: 10
County: New York

Public Profile

Adjuvance Technologies is a privately held biopharmaceutical company organized around enabling important and fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are the critical components are added to many vaccines to improve the immune response. Adjuvance Technologies has developed the capability to synthesize saponin adjuvants such as QS-21, a critical component of the AS01 adjuvant developed by GSK. In addition, principals of the firm have synthesized a novel analogue, TQL1055, with improved attributes compared to QS-21.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
1
Conversion Rate
25.00%
Phase I Dollars
$3,302,046
Phase II Dollars
$1,499,999
Total Awarded
$4,802,045

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $1,471,319
Project Title: Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine
2019 1 NIH $1,427,022
Project Title: Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine
2018 2 NIH $1,724,999
Project Title: Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant Titerquil
2017 1 NIH $223,002
Project Title: Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil on Influenza Vaccine Immunogenicity and Stability

Key People / Management

  Jay Tyler Martin -- CEO

  Sean Bennett -- CMO

  Jeffrey Gardner -- Co-Founder, Chief Business Officer

  Patrick Giljum -- CTO

  David Gin -- Co-Founder

  Philip O Livingston -- Co-Founder and Chief Scientific Officer

  Govindaswami Ragupathi

  Stephan Schulze -- CFO

Company News

Feb 21 2015
Roca biotechnologist joins California firm
Oct 27 2011
Sloan-Kettering Spinoff Adjuvance Gains Traction For Vaccine Tech